Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ROPXQ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-SLITRK6 mAb Ha15-1c25 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG2-kappa |
|||||
| Antigen Name | SLIT and NTRK-like protein 6 (SLITRK6) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HA15-1C25E [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 32.20% (Day 30) | High SLITRK6 expression (SLITRK6+++; IHC H-score=280) | ||
| Method Description |
CDX models were established by subcutaneous injection of between 2 and 10 million SW780, RT4 (ATCC) or NCI-H322M (NCI) cells in SCID mice. When the tumor volume reached approximately 230 mm3, a single dose of Ha15-1c25E, 5 mg/kg intravenously, was administered intravenously (iv) to the mice.
|
||||
| In Vivo Model | Bladder cancer CDX model | ||||
| In Vitro Model | Bladder carcinoma | RT-4 cells | CVCL_0036 | ||
HA15-1C25F [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 35.90% (Day 30) | High SLITRK6 expression (SLITRK6+++; IHC H-score=280) | ||
| Method Description |
CDX models were established by subcutaneous injection of between 2 and 10 million SW780, RT4 (ATCC) or NCI-H322M (NCI) cells in SCID mice. When the tumor volume reached approximately 230 mm3, a single dose of Ha15-1c25F, 5 mg/kg intravenously, was administered intravenously (iv) to the mice.
|
||||
| In Vivo Model | Bladder cancer CDX model | ||||
| In Vitro Model | Bladder cancer | Bladder cancer cells | Homo sapiens | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.